<DOC>
	<DOCNO>NCT02720692</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability N1539 variety post-surgical condition .</brief_summary>
	<brief_title>Evaluation N1539 Following Major Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Voluntarily provide write informed consent . Male female 18 80 year age , inclusive . Be plan undergo major elective surgery , expect require intravenous analgesia remain inpatient set least 2448 hour expect receive least two study dos . Female subject eligible follow apply : Not pregnant ; Not breastfeed ; Not able become pregnant ; Not plan become pregnant study 28 day follow ; Commit use acceptable form birth control duration study . Have body mass index ≤40 kg/m2 Be able understand study procedure , comply study procedure , agree participate study program . For oncology case , histologically confirm diagnosis primary solid tumor , affect one follow organ : breast , skin , colon , prostate , uterus , ovary , urethra , penis , vulva ; AND base clinical , laboratory , radiologic , pathologic , surgical finding , tumor confine primary organ , without evidence local , regional distal spread ; AND performance status able carry normal activity daily life without limitation . Have know allergy meloxicam excipient N1539 , aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) . Be schedule undergo cranial surgery , open heart procedure , type coronary artery bypass graft , organ transplant , surgical procedure NSAIDs contraindicate . Planned actual admission intensive care unit time study participation . Have clinically significant laboratory abnormality . Have history myocardial infarction within precede 12 month . Have history HIV , hepatitis B C. Have history clinical manifestation significant renal , hepatic , cardiovascular , metabolic , neurologic , psychiatric , respiratory , condition would preclude participation study . Have active recent ( within 6 month ) gastrointestinal ulceration bleed Have know bleed disorder may worsen administration NSAID . Have evidence clinically significant 12 lead ECG abnormality . Have history alcohol abuse ( regularly drink &gt; 4 unit alcohol per day ; 8 oz . beer , 3 oz . wine , 1 oz . spirit ) history prescription/illicit drug abuse within past 5 year . Have positive result urine drug screen cocaine PCP alcohol breath test indicative illicit drug alcohol abuse . Unable discontinue medication , stable dose least 14 day prior schedule surgical procedure , within 5 halflives specific prior medication ( , halflife know , within 48 hour ) dose study medication . Be unable discontinue herbal medication least 7 day prior surgery last dose study medication . Be receive lithium , combination furosemide either angiotensin convert enzyme inhibitor angiotensin receptor blocker Be currently receive treatment oral meloxicam ( Mobic® ) NSAID within 7 day prior surgery . Have receive investigational product within 30 day dose study medication . Have previously receive N1539 clinical trial , major surgery last 3 month would interfere study assessment . Have undergone expect undergo radiation therapy , chemotherapy , biological therapy cancer treatment , within 60 day prior screen , last study visit , approximately 30 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pain</keyword>
	<keyword>Analgesia</keyword>
	<keyword>N1539</keyword>
	<keyword>Phase 3</keyword>
</DOC>